Clinical Trials Logo

Neurofibromatosis Type 1 clinical trials

View clinical trials related to Neurofibromatosis Type 1.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05825365 Withdrawn - Clinical trials for Neurofibromatosis Type 1

Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, Phaseâ…¡, Double-Blinded, Placebo-Controlled Study

PROTECT
Start date: August 31, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II, multicenter, randomised, parallel, double-blind, placebo-controlled study assessing the efficacy and safety of the MEKi selumetinib compared with placebo in Chinese paediatric participants with post-operative NF1-associated PNs.

NCT ID: NCT03332030 Withdrawn - Clinical trials for Neurofibromatosis Type 1

Stem Cells in NF1 Patients With Tumors of the Central Nervous System

Start date: November 27, 2015
Phase:
Study type: Observational

Objectives 1. Establish an induced pluripotent stem cell (iPSC) bank for phenotypically well-characterized patients with NF1. 2. Develop isogenic NF1 wild-type (NF1+/+), NF1 heterozygous (NF1+/-) and NF1 homozygous (NF1-/-) iPSC lines from individual patients using CRISPR/CAS9 technology. 3. Differentiate and characterize disease-relevant brain cells such as excitatory and inhibitory neurons, astrocytes and oligodendrocytes from patient-specific iPSC lines. 4. Screen and identify the drug(s) that can reverse or alleviate the disease phenotypes.